Skip to main content

Table 6 Events at 6 months by antithrombotic treatment group

From: Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry

  Nothing
n = 93
UFH
n = 153
UFH + Abcx
n = 44
Abcx
n = 65
Bivalirudin
n = 24
Enoxaparin
n = 18
p
Death 9 (9.6) 10 (6.5) 5 (11.4) 5 (7.7) 2 (8.3) 1 (5.5) 0.4
Cardiac death 8 (8.6) 9 (5.9) 5 (11.4) 4 (6.1) 2 (8.3) 0 0.3
Infarction 1 (1) 3 (1.9) 2 (4.5) 1 (1.5) 3 (12.5) 0 0.04
Def./probable thrombosis 2 (2.1) 7 (4.6) 1 (2.2) 2 (3) 3 (12.5) 0 0.08
BARC >1 bleeding 10 (10.7) 10 (6.5) 3 (6.8) 12 (18.5) 1 (4.2) 2 (11.1) 0.01
BARC >2 bleeding 5 (5.4) 2 (1.3) 0 6 (9.2) 0 1 (5.5) 0.01
Brain hemorrhage 3 (3.2) 0 0 1 (1.5) 0 1 (5.5) 0.1
Revascularization 0 3 (1.9) 1 (2.2) 2 (3) 0 0 0.3
Stroke 1 (1) 0 0 1 (1.5) 0 0 0.7
  1. Abcx abciximab, BARC Bleeding Academic Research Consortium, UFH unfractionated heparin